Literature DB >> 11091055

Current and future antifungal therapy: new targets for antifungal therapy.

V T Andriole1.   

Abstract

Invasive fungal infections will continue to cause major complications in immunocompromized patients. At the moment, the expansion of antifungal drug research has occurred because there is a critical need for new antifungal agents to treat these life-threatening invasive fungal infections. The overview of the development of antifungal therapy which is provided here demonstrates the increased interest in this very special area of infectious diseases. Although we now have some newer and less toxic antifungal agents that are currently available for clinical use, their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not very good. Intense efforts in antifungal drug discovery are urgently needed to develop more promising and effective antifungal agents for use in the clinical arena.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091055     DOI: 10.1016/s0924-8579(00)00258-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

Review 1.  SPK-843 (Aparts/Kaken).

Authors:  Noer Kasanah; Mark T Hamann
Journal:  Curr Opin Investig Drugs       Date:  2005-08

Review 2.  Antifungal effect of plant extract and essential oil.

Authors:  Keyal Uma; Xin Huang; Bhatta Anil Kumar
Journal:  Chin J Integr Med       Date:  2016-09-03       Impact factor: 1.978

3.  Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells.

Authors:  Guo-Xian Wei; Libuse A Bobek
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 4.  Antifungal research strategies aiming for new targets.

Authors:  Glorivee Pagán-Mercado; Marielis E Rivera-Ruiz; Frances Segarra-Román; José R Rodríguez-Medina
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

5.  Isolation and partial characterization of antimicrobial compounds from a new strain Nonomuraea sp. NM94.

Authors:  Boubekeur Badji; Abdellah Mostefaoui; Nasserdine Sabaou; Ahmed Lebrihi; Florence Mathieu; Elisabeth Seguin; François Tillequin
Journal:  J Ind Microbiol Biotechnol       Date:  2007-02-22       Impact factor: 4.258

Review 6.  Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens.

Authors:  Ewa Ksiezopolska; Toni Gabaldón
Journal:  Genes (Basel)       Date:  2018-09-19       Impact factor: 4.096

7.  Antifungal Activity and Biocompatibility of α-AgVO3, α-Ag2WO4, and β-Ag2MoO4 Using a Three-Dimensional Coculture Model of the Oral Mucosa.

Authors:  Bruna Natália Alves da Silva Pimentel; Freddy Humberto Marin-Dett; Marcelo Assis; Paula Aboud Barbugli; Elson Longo; Carlos Eduardo Vergani
Journal:  Front Bioeng Biotechnol       Date:  2022-02-14

8.  In Vitro, Ex Vivo, and In Vivo Evaluation of Nanoparticle-Based Topical Formulation Against Candida albicans Infection.

Authors:  Sajid Khan Sadozai; Saeed Ahmad Khan; Abdul Baseer; Rooh Ullah; Alam Zeb; Marc Schneider
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

9.  Synthesis and antifungal activity of benzimidazole, benzotriazole and aminothiazole derivatives.

Authors:  S Khabnadideh; Z Rezaei; K Pakshir; K Zomorodian; N Ghafari
Journal:  Res Pharm Sci       Date:  2012-04

Review 10.  Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds.

Authors:  Małgorzata Bondaryk; Monika Staniszewska; Paulina Zielińska; Zofia Urbańczyk-Lipkowska
Journal:  J Fungi (Basel)       Date:  2017-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.